Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis

被引:21
|
作者
Qiu, Shiyuan [1 ,3 ]
Zhang, Hengci [2 ]
Yu, Sijie [3 ]
Yang, Qin [3 ]
Zhang, Gaofu [3 ]
Yang, Haiping [3 ]
Li, Qiu [3 ]
Wang, Mo [3 ]
机构
[1] Chongqing You You Baobei Womens & Childrens Hosp, Pediat Internal Med Dept, Chongqing, Peoples R China
[2] Guizhou Med Univ, Guiyang, Peoples R China
[3] Chongqing Med Univ, Dept Nephrol,Minist Educ,Key Lab Child Dev & Diso, Natl Clin Res Ctr Child Hlth & Disorders,China In, Childrens Hosp,Chongqing Key Lab Pediat, Chongqing, Peoples R China
关键词
Systemic lupus erythematosus; Lupus nephritis; Children; Prognosis; DISEASE-ACTIVITY STATE; ERYTHEMATOSUS; SLE; CLASSIFICATION; VALIDATION; REMISSION; EFFICACY; CRITERIA; CHILDREN; SAFETY;
D O I
10.1007/s00467-021-05164-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Pediatric lupus nephritis (pLN) is one of the most refractory secondary kidney diseases in childhood. The treat-to-target (T2T) strategy has become the standard treatment for systemic lupus erythematosus (SLE). This study reviewed clinical features, overall remission status, and factors affecting prognosis, to guide pLN management according to T2T strategy. Methods This single-center retrospective study studied 220 children diagnosed with LN from January 2012 to December 2018, with > 6-month follow-up data on 173 and complete data on 137 patients. Primary outcome was treatment failure (deterioration or no response) at the latest follow-up. Results The most common pLN manifestation was proteinuria (81.36%). Females presented more often with rash (P<0.001) and alopecia (P=0.026) than males. Class IV LN (33.33%) was the most common grade on kidney biopsy. Median follow-up was 27.20 months (IQR, 15.78-44.45 months). One-, 3-, and 5-year cumulative overall survival rates were 93.5%, 87.8%, and 86.5%, respectively. The 5-year cumulative kidney survival rate was 97.1%. Regarding initial therapy, efficacy of corticosteroids combined with immunosuppressive agents was significantly better than corticosteroids alone (P=0.010). Factors with P<0.05 in univariate analysis, including hypoalbuminemia, higher SCr at diagnosis, lower eGFR at diagnosis, anti-dsDNA positivity, heavy proteinuria, hypertension, nervous-system involvement, treatment non-compliance, and SLEDAI-2K score, were used for logistic regression analysis. Logistic regression analysis showed hypertension (OR=0.845, P=0.011), nervous-system involvement (OR=4.240, P=0.005), treatment non-compliance (OR=6.433, P=0.001), and lower estimated glomerular filtration rate at diagnosis (OR=1.020, P=0.021) affected prognosis. At end of follow-up, 34.31% achieved varying levels of remission, and 8.76% were in low disease activity state (LDAS). Conclusions pLN usually presented with proteinuria, and class IV LN was the dominant pathology. Hypertension, nervous-system involvement, treatment non-compliance, and lower eGFR at diagnosis were independent risk factors for poor prognosis of kidney outcomes. Compared with renal remission rate and cumulative overall survival rate, the proportion of targets achieved was not ideal, suggesting T2T strategy should be used to guide pLN management.
引用
收藏
页码:367 / 376
页数:10
相关论文
共 50 条
  • [21] Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab
    Gomez, Alvaro
    Lindblom, Julius
    Parodis, Ioannis
    Bertsias, George
    RHEUMATOLOGY, 2025,
  • [22] LUPUS NEPHRITIS : CLINICAL MANIFESTATIONS AND RISK FACTORS
    Kechida, M.
    Vilalba, N. Lorenzo
    Mesfar, R.
    Funes, Y. Alvarado
    Klii, R.
    Hammami, S.
    Khochtali, I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (01) : S94 - S94
  • [23] Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis
    Sun, F.
    Zhang, D.
    Wang, H.
    Liu, Z.
    Geng, S.
    Wang, X.
    Li, T.
    Wan, W.
    Lu, L.
    Teng, X.
    Morel, L.
    Ye, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (09) : 1733 - 1737
  • [24] Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis
    Kisaoglu, Hakan
    Baba, Ozge
    Kalyoncu, Mukaddes
    PEDIATRIC NEPHROLOGY, 2023, 38 (04) : 1167 - 1175
  • [25] Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force
    Piga, Matteo
    Parodis, Ioannis
    Touma, Zahi
    Legge, Alexandra
    Ugarte-Gil, Manuel F.
    Hmamouchi, Ihsane
    Puerta, Jose A. Gomez
    Devilliers, Herve
    Zen, Margherita
    Cho, Jiacai
    Ziade, Nelly
    Mucke, Johanna
    Toro-Gutierrez, Carlos Enrique
    Izuka, Shinji
    Korsten, Peter
    Kane, Baidy S. Y.
    Golder, Vera
    Chong, Benjamin F.
    Pons-Estel, Guillermo
    Chasset, Francois
    Arnaud, Laurent
    AUTOIMMUNITY REVIEWS, 2025, 24 (05)
  • [26] Implementation of treat-to-target principles in the management of systemic lupus erythematosus
    Zirkzee, E.
    Bonte-Mineur, F.
    Kok, M.
    LUPUS, 2018, 27 (07) : 1218 - 1219
  • [27] Treat-to-target in systemic lupus erythematosus: where are we today?
    Mosca, M.
    Boumpas, D.
    Bruce, I. N.
    Cervera, R.
    Czirjak, L.
    Doerner, T.
    Houssiau, F.
    Jacobsen, S.
    Schneider, M.
    Smolen, J. S.
    Voskuyl, A. E.
    van Vollenhoven, R. F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : S112 - S115
  • [28] Analysis of clinical manifestations and pathology of lupus nephritis: a retrospective review of 82 cases
    Guo, Qiaoyan
    Lu, Xuehong
    Miao, Lining
    Wu, Man
    Lu, Shan
    Luo, Ping
    CLINICAL RHEUMATOLOGY, 2010, 29 (10) : 1175 - 1180
  • [29] Prognosis and Predictors of Convulsion among Pediatric Lupus Nephritis Patients
    Beiraghdar, Fatemeh
    Maddani, Abbas
    Taheri, Saeed
    Sharifi-Bonab, Mir Mohsen
    Esfahani, Taher
    Panahi, Yunes
    Einollahi, Behzad
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2009, 20 (03) : 424 - 428
  • [30] Clinical analysis of multi-target treatment for complex lupus nephritis
    Ye, Feng
    Wang, Shanzhi
    Wang, Min
    Wang, Huanan
    Guo, Feng
    Li, Guoquan
    Liu, Nan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (01): : 687 - 692